drugset / Trial / NCT00080210
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
RandomizedSingle-groupOpen-labelTreatment
Summary
This is a randomized, open-label, multicenter, parallel-groups study of multiple intravenous doses of Puricase, administered intravenously, in 40 patients with symptomatic gout. Subjects must wash out of any uric acid-lowering agents for one week before being dosed, and must refrain from using such agents throughout the study.
Timeline
- Start
- 2004-03
- Primary completion
- —
- Completion
- 2005-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegloticase | Protein / enzyme biologic | 4 mg | Intravenous |
| Subject | Pegloticase | Protein / enzyme biologic | 8 mg | Intravenous |
| Subject | Pegloticase | Protein / enzyme biologic | 12 mg | Intravenous |